Alaunos Therapeutics, Inc. (TCRT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.82. The rating moved from Oversold to Strong Oversold on September 30, 2026.

• Public ratingStrong Oversold (as of October 3, 2026)
• Last close$0.82
• Last changeMoved from Oversold to Strong Oversold on September 30, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Alaunos Therapeutics, Inc. (TCRT) exhibits typical microcap biotech risk: limited public disclosure and likely constrained cash runway amid a market environment that is risk‑averse toward early‑stage healthcare names. Near‑term upside depends heavily on discrete clinical or partnering catalysts; absent those, policy headwinds around drug pricing, a cooled IPO market, and thin liquidity point to downside vulnerability. Investors should expect potential dilution, volatile intraday moves, and dependence on milestone events to change the risk profile.

Key factors

• Small-cap clinical/specialty biotech profile with limited publicly available financial filings and visibility into cash runway
• Risk-off market tone and cooled IPO window reducing appetite for early-stage healthcare equities
• Policy pressure on drug pricing (Medicare negotiation/IRA) increases downstream pricing and access uncertainty for specialty therapies
• Potential upside from any positive clinical readout, partnership, or licensing deal that could de‑risk programs and provide non‑dilutive capital
• Low liquidity and thin trading volume typical for microcap tickers, amplifying price moves on limited flow
• No recent EDGAR or social sentiment analysis available, increasing information asymmetry for investors

Risks

• Insufficient cash runway requiring dilutive financing or unfavorable partnerships
• Clinical trial delays, negative readouts, or regulatory setbacks that would materially reduce value
• Adverse policy/payer actions (Medicare negotiations, reimbursement constraints) compressing potential future revenues
• Competitive pressure from larger biologics and combo-therapy entrants that could limit market share
• High market volatility and sector-specific risk-off flows leading to sharp share-price declines
• Limited analyst coverage and low retail/institutional interest increasing susceptibility to outsized swings

Latest MarketMoodz coverage

• Alaunos' Obesity Data Shows Promise in Mice, Shares Dip2026-03-02

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.